Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2015

Open Access 01-12-2015 | Case report

Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison’s disease – favourable response to dietary management: a case report

Authors: Kristina S Petersen, R. Louise Rushworth, Peter M Clifton, David J Torpy

Published in: BMC Endocrine Disorders | Issue 1/2015

Login to get access

Abstract

Background

Addison’s disease, or primary adrenal insufficiency, is often associated with reduced well-being and fatigue despite use of currently recommended adrenal hormone replacement. Hypoglycaemia is a known manifestation of glucocorticoid deficiency, but is generally considered rare in adults and not relevant to troubling ongoing symptoms in patients with Addison’s disease.

Case presentation

A 43 year old woman with a three year history of Addison’s disease complained of severe morning fatigue and headaches, despite standard glucocorticoid replacement therapy in the form of thrice daily hydrocortisone and mineralocorticoid replacement with fludrocortisone. Alternative glucocorticoid replacement regimens and the addition of dehydroepiandrosterone replacement therapy had no effect. Nocturnal hypoglycaemia was suspected and a 4-day continuous glucose monitor system (CGMS) revealed hypoglycaemia (interstitial glucose < 2.2 mmol/L) between 0200–0400 h on 3 of 4 days. The patient was counselled to take an evening snack designed to ensure slow absorption of ingested carbohydrates. Nocturnal hypoglycaemia was then absent on follow up CGMS assessment. The patient noted a marked symptomatic improvement in morning symptoms, but with persistent fatigue during the day.

Conclusion

Currently, the best strategy for control of non-specific symptoms in treated Addison’s disease is unknown, but it may be that investigation for hypoglycaemia and treatment, where necessary, could assist some sufferers to achieve improved wellbeing. A systematic study of this phenomenon in Addison’s disease is required.
Literature
1.
go back to reference Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol. 2002;56(5):581–8. Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol. 2002;56(5):581–8.
2.
go back to reference Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the quality of life in autoimmune Addison's disease? Horm Metab Res. 2013;45(2):92–5.PubMed Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the quality of life in autoimmune Addison's disease? Horm Metab Res. 2013;45(2):92–5.PubMed
3.
go back to reference Christiansen JJ, Djurhuus CB, Gravholt CH, Iversen P, Christiansen JS, Schmitz O, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007;92(9):3553–9.PubMed Christiansen JJ, Djurhuus CB, Gravholt CH, Iversen P, Christiansen JS, Schmitz O, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007;92(9):3553–9.PubMed
4.
go back to reference Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, et al. Influence of hydrocortisone dosage scheme on health‐related quality of life in patients with adrenal insufficiency. Clin Endocrinol. 2010;72(3):297–304. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, et al. Influence of hydrocortisone dosage scheme on health‐related quality of life in patients with adrenal insufficiency. Clin Endocrinol. 2010;72(3):297–304.
5.
go back to reference Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160(6):993–1002.PubMed Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160(6):993–1002.PubMed
6.
go back to reference Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaelsson K, Ludvigsson JF. Risk of hip fracture in Addison’s disease: a population‐based cohort study. J Intern Med. 2011;270(2):187–95.PubMed Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaelsson K, Ludvigsson JF. Risk of hip fracture in Addison’s disease: a population‐based cohort study. J Intern Med. 2011;270(2):187–95.PubMed
7.
go back to reference Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91(10):3954–61.PubMed Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91(10):3954–61.PubMed
8.
go back to reference Rushworth RL, Torpy DJ. Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res. 2015;47(9):637–42.PubMed Rushworth RL, Torpy DJ. Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res. 2015;47(9):637–42.PubMed
9.
go back to reference Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that the Use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm Metab Res. 2015;47(6):427–32.PubMed Rushworth RL, Torpy DJ. Adrenal insufficiency in Australia: is it possible that the Use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm Metab Res. 2015;47(6):427–32.PubMed
10.
go back to reference Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet. 2010;49(7):455–63.PubMed Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet. 2010;49(7):455–63.PubMed
11.
go back to reference Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.PubMed Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.PubMed
12.
go back to reference Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200–7.PubMed Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200–7.PubMed
13.
go back to reference Fietta P. Glucocorticoids and brain functions. Rivista Di Biologia. 2006;100(3):403–18. Fietta P. Glucocorticoids and brain functions. Rivista Di Biologia. 2006;100(3):403–18.
14.
go back to reference Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol. 1997;46(3):255–61. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol. 1997;46(3):255–61.
15.
go back to reference Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol. 1997;46(3):263–8. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol. 1997;46(3):263–8.
16.
go back to reference Mah PM, Jenkins RC, Rostami‐Hodjegan A, Newell‐Price J, Doane A, Ibbotson V, et al. Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61(3):367–75. Mah PM, Jenkins RC, Rostami‐Hodjegan A, Newell‐Price J, Doane A, Ibbotson V, et al. Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61(3):367–75.
17.
go back to reference Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Investig. 2003;26(11):1071–5. Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Investig. 2003;26(11):1071–5.
18.
go back to reference Barbetta L, Dall’Asta C, Re T, Libe R, Costa E, Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Investig. 2005;28(9):632–7. Barbetta L, Dall’Asta C, Re T, Libe R, Costa E, Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Investig. 2005;28(9):632–7.
19.
go back to reference Ekman B, Bachrach‐Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double‐blind, crossover study comparing two‐and four‐dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol. 2012;77(1):18–25. Ekman B, Bachrach‐Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double‐blind, crossover study comparing two‐and four‐dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol. 2012;77(1):18–25.
20.
go back to reference Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Investig. 2004;27(5):449–54. Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Investig. 2004;27(5):449–54.
21.
go back to reference Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr Disord. 2012;12(1):8.PubMedPubMedCentral Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr Disord. 2012;12(1):8.PubMedPubMedCentral
22.
go back to reference Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):1548–54.PubMedPubMedCentral Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):1548–54.PubMedPubMedCentral
23.
go back to reference Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, et al. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 2015:1–9. Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, et al. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 2015:1–9.
24.
go back to reference Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley L-A, Digweed D, et al. A phase 2 study of chronocort®, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2014;100(3):1137–45.PubMed Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley L-A, Digweed D, et al. A phase 2 study of chronocort®, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2014;100(3):1137–45.PubMed
25.
go back to reference Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161(1):119–30.PubMed Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161(1):119–30.PubMed
26.
go back to reference Øksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014;99(5):1665–74.PubMed Øksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014;99(5):1665–74.PubMed
27.
go back to reference Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99(11):4149–57.PubMed Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99(11):4149–57.PubMed
28.
go back to reference Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676–81.PubMed Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676–81.PubMed
29.
go back to reference Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. 2011;96(6):E925–8.PubMed Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. 2011;96(6):E925–8.PubMed
30.
go back to reference Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur J Endocrinol. 2009;160(6):919–24.PubMed Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur J Endocrinol. 2009;160(6):919–24.PubMed
31.
go back to reference Plat L, Leproult R, L’Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, et al. Metabolic effects of short-term elevations of plasma cortisol Are more pronounced in the evening than in the morning 1. J Clin Endocrinol Metab. 1999;84(9):3082–92.PubMed Plat L, Leproult R, L’Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, et al. Metabolic effects of short-term elevations of plasma cortisol Are more pronounced in the evening than in the morning 1. J Clin Endocrinol Metab. 1999;84(9):3082–92.PubMed
32.
go back to reference Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996;81(7):2468–73.PubMed Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996;81(7):2468–73.PubMed
33.
go back to reference Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Fery F, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996;270(1):E36–42.PubMed Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Fery F, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996;270(1):E36–42.PubMed
34.
go back to reference Meyer G, Hackemann A, Reusch J, Badenhoop K. Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison’s disease). Diabetes Technol Ther. 2012;14(5):386–8.PubMedPubMedCentral Meyer G, Hackemann A, Reusch J, Badenhoop K. Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison’s disease). Diabetes Technol Ther. 2012;14(5):386–8.PubMedPubMedCentral
Metadata
Title
Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison’s disease – favourable response to dietary management: a case report
Authors
Kristina S Petersen
R. Louise Rushworth
Peter M Clifton
David J Torpy
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2015
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-015-0058-6

Other articles of this Issue 1/2015

BMC Endocrine Disorders 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.